GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » EV-to-EBITDA

Gland Pharma (NSE:GLAND) EV-to-EBITDA : 21.93 (As of May. 17, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gland Pharma's enterprise value is ₹274,608 Mil. Gland Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹12,522 Mil. Therefore, Gland Pharma's EV-to-EBITDA for today is 21.93.

The historical rank and industry rank for Gland Pharma's EV-to-EBITDA or its related term are showing as below:

NSE:GLAND' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.47   Med: 24.99   Max: 47.22
Current: 21.93

During the past 6 years, the highest EV-to-EBITDA of Gland Pharma was 47.22. The lowest was 9.47. And the median was 24.99.

NSE:GLAND's EV-to-EBITDA is ranked worse than
68.97% of 709 companies
in the Drug Manufacturers industry
Industry Median: 14.88 vs NSE:GLAND: 21.93

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Gland Pharma's stock price is ₹1779.65. Gland Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹39.980. Therefore, Gland Pharma's PE Ratio for today is 44.51.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Gland Pharma EV-to-EBITDA Historical Data

The historical data trend for Gland Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma EV-to-EBITDA Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial - - 26.14 29.18 14.18

Gland Pharma Quarterly Data
Mar18 Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.67 14.18 14.65 21.28 25.31

Competitive Comparison of Gland Pharma's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Gland Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gland Pharma's EV-to-EBITDA falls into.



Gland Pharma EV-to-EBITDA Calculation

Gland Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=274607.732/12522.47
=21.93

Gland Pharma's current Enterprise Value is ₹274,608 Mil.
Gland Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹12,522 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gland Pharma  (NSE:GLAND) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Gland Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1779.65/39.980
=44.51

Gland Pharma's share price for today is ₹1779.65.
Gland Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹39.980.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Gland Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gland Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gland Pharma (NSE:GLAND) Business Description

Traded in Other Exchanges
Address
Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines